Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectivel...

Full description

Saved in:
Bibliographic Details
Published innpj vaccines Vol. 5; no. 1; p. 14
Main Authors Mariz, Filipe Colaço, Bender, Noemi, Anantharaman, Devasena, Basu, Partha, Bhatla, Neerja, Pillai, Madhavan Radhakrisna, Prabhu, Priya R, Sankaranarayanan, Rengaswamy, Eriksson, Tiina, Pawlita, Michael, Prager, Kristina, Sehr, Peter, Waterboer, Tim, Müller, Martin, Lehtinen, Matti
Format Journal Article
LanguageEnglish
Published England 14.02.2020
Online AccessGet full text

Cover

More Information
Summary:We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine. The correlation of bivalent vaccine-induced HPV45 ab-levels with HPV16/18 ab-levels was stronger than that of corresponding quadrivalent vaccine-induced ab-levels, suggesting a qualitatively different cross-reactive response. Our findings on the comparison of the immunogenicity of two HPV vaccine tested in two different populations indicate that further head-to-head studies are warranted.
ISSN:2059-0105